{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:31:29Z","timestamp":1789723889070,"version":"4.0.1"},"reference-count":18,"publisher":"American Physiological Society","issue":"9","funder":[{"name":"HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","award":["R01AR051598 10"],"award-info":[{"award-number":["R01AR051598 10"]}]},{"name":"The National Instiute of Health (NIH)","award":["C76 HF00201"],"award-info":[{"award-number":["C76 HF00201"]}]},{"name":"The National Institute of Health (NIH)","award":["P30 HD002528"],"award-info":[{"award-number":["P30 HD002528"]}]},{"name":"The National Institute of Health (NIH)","award":["S10 RR29577"],"award-info":[{"award-number":["S10 RR29577"]}]},{"name":"The National Institute of Health (NIH)","award":["P30 AG035982"],"award-info":[{"award-number":["P30 AG035982"]}]},{"name":"The Nationasl Institute of Health (NIH)","award":["UL1 TR000001"],"award-info":[{"award-number":["UL1 TR000001"]}]},{"name":"The Hoglund Family Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Renal Physiology"],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:p>\n                    Nephrogenic systemic fibrosis (NSF) is a devastating condition associated with gadolinium (Gd\n                    <jats:sup>3+<\/jats:sup>\n                    )-based contrast agents (GBCAs) in patients with kidney disease. The release of toxic Gd\n                    <jats:sup>3+<\/jats:sup>\n                    from GBCAs likely plays a major role in NSF pathophysiology. The cause and etiology of Gd\n                    <jats:sup>3+<\/jats:sup>\n                    release from GBCAs is unknown. Increased Acidic Serine Aspartate Rich MEPE-associated peptides (ASARM peptides) induce bone mineralization abnormalities and contribute to renal phosphate-handling defects in inherited hypophosphatemic rickets and tumor-induced osteomalacia. The proteolytic cleavage of related bone matrix proteins with ASARM motifs results in release of ASARM peptide into bone and circulation. ASARM peptides are acidic, reactive, phosphorylated inhibitors of mineralization that bind Ca\n                    <jats:sup>2+<\/jats:sup>\n                    and hydroxyapatite. Since the ionic radius of Gd\n                    <jats:sup>3+<\/jats:sup>\n                    is close to that of Ca\n                    <jats:sup>2+<\/jats:sup>\n                    , we hypothesized that ASARM peptides increase the risk of NSF by inducing release of Gd\n                    <jats:sup>3+<\/jats:sup>\n                    from GBCAs. Here, we show 1) ASARM peptides bind and induce release of Gd\n                    <jats:sup>3+<\/jats:sup>\n                    from GBCAs in vitro and in vivo; 2) A bioengineered peptide (SPR4) stabilizes the Gd\n                    <jats:sup>3+<\/jats:sup>\n                    -GBCA complex by specifically binding to ASARM peptide in vitro and in vivo; and 3) SPR4 peptide infusion prevents GBCA-induced NSF-like pathology in a murine model with increased ASARM peptide (Hyp mouse). We conclude ASARM peptides may play a role in NSF and SPR4 peptide is a candidate adjuvant for preventing or reducing risk of disease.\n                  <\/jats:p>","DOI":"10.1152\/ajprenal.00201.2015","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T21:34:25Z","timestamp":1441229665000},"page":"F764-F769","source":"Crossref","is-referenced-by-count":13,"title":["Do ASARM peptides play a role in nephrogenic systemic fibrosis?"],"prefix":"10.1152","volume":"309","author":[{"given":"Peter S. N.","family":"Rowe","sequence":"first","affiliation":[{"name":"The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesya V.","family":"Zelenchuk","sequence":"additional","affiliation":[{"name":"The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Laurence","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry, University of Kansas, Kansas City, Lawrence, Kansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Lee","sequence":"additional","affiliation":[{"name":"Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, Kansas;"},{"name":"Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, Kansas;"},{"name":"Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen T.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"24","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080601"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1766"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu151"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-4226-2"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0216"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00304.2010"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01585.x"},{"key":"B8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/RLI.0b013e3181f54044","volume":"46","author":"Fretellier N","year":"2011","journal-title":"Invest Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000245725.94887.8d"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/10408444.2014.955568"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2461071267"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-1205"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i1.50"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.09.015"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056749"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2014.11.011"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.05.030"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097326"}],"container-title":["American Journal of Physiology-Renal Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajprenal.00201.2015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T21:16:54Z","timestamp":1567977414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajprenal.00201.2015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,1]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,11,1]]}},"alternative-id":["10.1152\/ajprenal.00201.2015"],"URL":"https:\/\/doi.org\/10.1152\/ajprenal.00201.2015","relation":{},"ISSN":["1931-857X","1522-1466"],"issn-type":[{"value":"1931-857X","type":"print"},{"value":"1522-1466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,1]]}}}